InvestorsObserver
×
News Home

10X Genomics Inc (TXG) Stock: Do Analysts Think You Should Accumulate?

Wednesday, May 18, 2022 02:36 PM | InvestorsObserver Analysts

Mentioned in this article

10X Genomics Inc (TXG) Stock: Do Analysts Think You Should Accumulate?

Analysts who follow 10X Genomics Inc (TXG) on average expect it to gain 102.83% over the next twelve months. Those same analysts give the stock an average rating of Strong Buy. That average rating earns TXG an Analyst Ranking of 59, which means it ranks higher than 59 of stocks, based on data compiled by InvestorsObserver.

Overall Score - 4.6
Wall Street analysts are rating TXG a Strong Buy today. Find out what this means to you and get the rest of the rankings on TXG!

Why are Analyst Ratings Important?

Fundamental research of the underlying health of a company can be an extremely useful resource when making investment decisions. Analysts observe growth prospects and forecasted earnings of companies to gain a comprehensive view of particular industries. This data allows traders to react before numbers are officially reported. InvestorsObserver takes the ratings from these analysts and percentile ranks those aveages. This allows you to compare stocks extensively and in more detail than the common buy/hold/sell ratings.

What's Happening With 10X Genomics Inc Stock Today?

10X Genomics Inc (TXG) stock is trading at $48.07 as of 2:27 PM on Wednesday, May 18, a drop of -$1.40, or -2.82% from the previous closing price of $49.46. The stock has traded between $47.62 and $50.32 so far today. Volume today is low. So far 700,318 shares have traded compared to average volume of 1,641,317 shares. Click Here to get the full Stock Report for 10X Genomics Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App